
1. A compound represented by:



wherein

R^{11}, R^{12} and R^{13} are each independently selected from the group consisting of H, halogen, C_{1-3}alkoxy, and C_{1-3}alkyl (optionally substituted by one, two or three halogens);

X^1 is OH or NH_2,

X^2 is H or OH;

and pharmaceutically acceptable salts, stereoisomers and hydrates thereof.


2. The compound of claim 1, wherein the halogen, for each occurrence, is independently selected from the group consisting of Cl, Br, and F.

3. The compound of claim 1 or 2, wherein X^2 is OH and X^1 is NH_2

4. The compound of any one of claims 1-3, wherein each of R^{11}, R^{12}, and R^{13} is H.

5. The compound of any one of claims 1-4, wherein R^{11} and R^{13} is H, and R^{12} is selected from the group consisting of F, Br, Cl, CH_3, CF_3, and -OCH_3.

6. A compound represented by:



wherein


R^1, R^2, R^3, and R^4 are each independently selected from the group consisting of hydrogen; halogen, C_1-C_6alkyl, and -OH;

R^5 is -CH_2-phenyl (wherein the phenyl is optionally substituted by one, two, or three substituents selected from the group consisting of halogen, C_{1-3}alkoxy, and C_{1-3}alkyl (optionally substituted by one, two or three halogens)), provided that R^5 is -CH_2-phenyl when R_1 and R_3 are -OH and R_2 and R_4 are methyl; and


X is selected from the group consisting of OR^x and NR^XR^X, wherein R^X is independently selected, for each occurrence, from the group consisting of hydrogen, and C_1-C_6alkyl;


pharmaceutically acceptable salts, stereoisomers, and hydrates thereof.

7. The compound of claim 6 represented by:




8. The compound of claim 6 represented by:







,



,



, or



.

9. A pharmaceutical composition, comprising:

a therapeutically effective amount of a compound of any one of claims 1-8 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is an injectable composition.

11. Use of a compound of any one of claims 1-8 in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, ADHD, schizophrenia, or anxiety.

12. Use of a compound of any one of claims 1-5 in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, ADHD, schizophrenia, or anxiety, wherein the medicament is to be administered orally.

13. Use of a compound of any one of claims 7 or 8 in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, ADHD, schizophrenia, or anxiety, wherein the medicament is to be administered subcutaneously or intravenously.